PHILADELPHIA--(BUSINESS WIRE)--Nov 7, 2023--BioPhy today launched its AI operating system that radically accelerates the identification and development of the most promising drug candidates. By combining scientific, clinical and regulatory insights with a proprietary operational assessment ...
BURLINGTON, Mass.--(BUSINESS WIRE)--Nov 7, 2023--Cardurion Pharmaceuticals, Inc. (鈥淐ardurion鈥� or 鈥渢he Company鈥�), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today ...
MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 7, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.鈥淚t has been an exciting time at Sage as we prepare for the upcoming commercial launch of ZURZUVAE, ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Nov 7, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it ...
PARAMUS, N.J.--(BUSINESS WIRE)--Nov 3, 2023--Starton Therapeutics Inc. (鈥淪tarton鈥� or 鈥渢he Company鈥�), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell ...